Cargando…

Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma

Mantle cell lymphoma (MCL) is a clinically heterogeneous B cell malignancy for which a variety of prognostic factors have been proposed. Previously, a digital gene expression profiling “proliferation signature” capable of risk stratifying MCL was identified and subsequently developed into a multi-an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramsower, Colleen A., Maguire, Alanna, Robetorye, Ryan S., Feldman, Andrew L., Syrbu, Sergei I., Rosenthal, Allison C., Rimsza, Lisa M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661397/ https://www.ncbi.nlm.nih.gov/pubmed/33193905 http://dx.doi.org/10.1007/s12308-020-00418-4

Ejemplares similares

PB2380: DEVELOPING GENOMIC TESTS THAT GUIDE LARGE B-CELL LYMPHOMA DIAGNOSIS AND TREATMENT: LYMPH2CX AND LYMPH3CX ASSAYS
por: Robetorye, Ryan S., et al.
Publicado: (2023)

P1287: DISTINGUISHING BETWEEN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA USING THE LYMPH3CX GENE EXPRESSION PROFILING ASSAY
por: Robetorye, R. S., et al.
Publicado: (2022)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)

Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
por: Shanbhag, Satish, et al.
Publicado: (2010)

Transformation of FL into DLBCL with a PMBL gene expression signature
por: Loveday, Tristan, et al.
Publicado: (2022)

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
por: Serna, Angel, et al.
Publicado: (2022)

Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry
por: Tilch, Marie-Kristin, et al.
Publicado: (2022)

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3
por: Eskelund, Christian Winther, et al.
Publicado: (2020)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
por: Beitinjaneh, Amer, et al.
Publicado: (2022)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial
por: Ferrero, Simone, et al.
Publicado: (2023)

Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma
por: Gong, Yi, et al.
Publicado: (2017)

Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network
por: Klapper, Wolfram, et al.
Publicado: (2009)

Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year
por: Herrero-Vicent, Carmen, et al.
Publicado: (2016)

Erratum: Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year
por: Herrero-Vicent, Carmen, et al.
Publicado: (2016)

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma
por: Ferrero, Simone, et al.
Publicado: (2022)

Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins
por: Li, Yijing, et al.
Publicado: (2023)

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
por: Wang, Michael, et al.
Publicado: (2017)

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
por: Arcaini, Luca, et al.
Publicado: (2017)

Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network
por: Drandi, Daniela, et al.
Publicado: (2020)

Longitudinal CT Imaging to Explore the Predictive Power of 3D Radiomic Tumour Heterogeneity in Precise Imaging of Mantle Cell Lymphoma (MCL)
por: Lisson, Catharina Silvia, et al.
Publicado: (2022)

A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
por: Ghaderi, Amineh, et al.
Publicado: (2022)

Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada
por: Anglin, Peter, et al.
Publicado: (2023)

S221: LONG-TERM RESULTS OF THE FIL MCL0208 TRIAL COMPARING LENALIDOMIDE MAINTENANCE (LEN) VS OBSERVATION (OBS) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MANTLE CELL LYMPHOMA (MCL)
por: Ladetto, Marco, et al.
Publicado: (2023)

IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
por: Sancho, Juan-Manuel, et al.
Publicado: (2022)

Smoldering mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2017)

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
por: Rule, Simon A., et al.
Publicado: (2019)

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial
por: Bomben, Riccardo, et al.
Publicado: (2018)

Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria
por: Harmanen, Minna, et al.
Publicado: (2023)

Mantle cell lymphoma with features of marginal-zone lymphoma
por: Randen, Ulla, et al.
Publicado: (2011)

Primary gastric mantle cell lymphoma
por: Petranovic, Duska, et al.
Publicado: (2012)

Mantle cell lymphoma with skin involvement
por: Kalińska-Bienias, Agnieszka, et al.
Publicado: (2015)

Esophageal location of mantle cell lymphoma
por: Michopoulos, Spyros
Publicado: (2016)

Tracheobronchial involvement of mantle cell lymphoma
por: Tong, Lin, et al.
Publicado: (2018)

Mantle Cell Lymphoma Case Report
por: Podzolkov, V.I., et al.
Publicado: (2018)

Educational Case: Mantle Cell Lymphoma
por: Mai, Brenda, et al.
Publicado: (2020)

Emerging therapies in mantle cell lymphoma
por: Hanel, Walter, et al.
Publicado: (2020)

Tackling Mantle Cell Lymphoma in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_29jm0qk9qncnl4n3orhu7b3hrq